Literature DB >> 2297315

Collagen shield heparin delivery for prevention of postoperative fibrin.

T G Murray1, W H Stern, D H Chin, E A MacGowan-Smith.   

Abstract

We studied collagen shield heparin delivery to the rabbit eye utilizing radiolabeled heparin as well as a fibrin inhibition assay. Radiolabeled heparin studies revealed significant tritium delivery to the cornea, aqueous, and iris, with only trace levels detectable for the lens, vitreous, and sclera. An aqueous fibrin inhibition assay revealed that a single collagen shield soaked in heparin achieved anterior chamber anticoagulant levels that paralleled the time course of the radiolabeled heparin delivery and resulted in fibrin inhibition during the 6-hour study period. Subconjunctival heparin injection did not alter baseline aqueous anticoagulant activity. No complications related to collagen shield heparin delivery were encountered. These studies suggest that a heparin-hydrated collagen shield may prevent postoperative fibrin formation in eyes at risk for this complication, including eyes undergoing surgery for the complications of proliferative diabetic retinopathy proliferative vitreoretinopathy, and glaucoma filtration surgery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297315     DOI: 10.1001/archopht.1990.01070030110039

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes.

Authors:  Lixin Xie; Jie Sun; Zhan Yao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-22       Impact factor: 3.117

2.  Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice.

Authors:  S Frizelle; J Schwarz; S A Huber; K Leslie
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 3.  Posterior Capsule Opacification: A Review of Experimental Studies.

Authors:  Joanna Konopińska; Maryla Młynarczyk; Diana Anna Dmuchowska; Iwona Obuchowska
Journal:  J Clin Med       Date:  2021-06-27       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.